The objective of this program is further improvement in the treatment and management of cancer patients. This will be sought through the development of new agents and regimens and means for circumvention of acquired resistance in patients under treatment for various neoplastic disorders. To accomplish this goal, a series of coordinated, multidisciplinary investigational activities are proposed. These extend our advances in the following areas. New classical folate analogues will be evaluated as antitumor agents. The design of new homologues of methotrexate and 10- ethyl-10-deazaminopterin (10EDAM) incorporates structural features found to be important for the highly promising clinical activity of 10EDAM in nonsmall-cell lung cancer patients. Studies are also proposed on newly designed analogues of folic acid and tetrahydrofolate that are inhibitors of combinations of antifolates with DNA interacting agents. The synthesis and evaluation are proposed of novel classes of intercalating agents with alkylating capability that are among those already developed in this program that potently inhibit either topoisomerase I or II. Aspects of the mechanism of action and acquired resistance of these new folate analogues and new topoisomerase inhibitors are also sought. A major effort is also proposed on the problem of multidrug resistance (MDR). These studies will focus on """"""""early events"""""""" in the initiation of MDR at the level of P- glycoprotein and the relationship between these events and neoplastic potential and cellular differentiation. MDR variants will be studied with the view to characterizing two prevalent P-glycoproteins, P170 and P180 and a new candidate, MS-1, putatively associated with MDR, that appears to be a differentiation marker during maturation of murine intestinal epithelial cells. These studies will examine aspects of P-glycoprotein gene expression and transcriptional regulation as well as biochemical mechanisms at both laboratory and clinical levels. The latter will address a number of questions related to P-glycoprotein-mediated MDR and its circumvention in the treatment and pathogenesis of leukemia and of a few selected solid tumor using molecular probes, immuno-histochemistry and flow cytometry. Facilities and resources provided in two Core Laboratories will allow rapid biological evaluation and clinical exploitation of promising new findings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018856-18
Application #
3092796
Study Section
Special Emphasis Panel (SRC (C3))
Project Start
1985-01-01
Project End
1995-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
18
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
He, Ling; Chang, He-Xi; Chou, Ting-Chao et al. (2003) Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern--synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. Eur J Med Chem 38:101-7
Johnson, R A; Ince, T A; Scotto, K W (2001) Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276:27716-20
Lin, Y; Ince, T A; Scotto, K W (2001) Optimization of a versatile in vitro transcription assay for the expression of multiple start site TATA-less promoters. Biochemistry 40:12959-66
Chang, H X; Chou, T C; Savaraj, N et al. (1999) Design of antineoplastic agents based on the ""2-phenylnaphthalene-type"" structural pattern. 4. Synthesis and biological activity of 2-chloro-3-(substituted phenoxy)-1, 4-naphthoquinones and related 5,8-dihydroxy-1,4-naphthoquinones. J Med Chem 42:405-8
Piper, J R; Ramamurthy, B; Johnson, C A et al. (1996) Analogues of 10-deazaaminopterin and 5-alkyl-5,10-dideazaaminopterin with the 4-substituted 1-naphthoyl group in the place of 4-substituted benzoyl. J Med Chem 39:614-8
Chou, T C; Otter, G M; Sirotnak, F M (1996) Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 37:222-8
Kim, J Y; Su, T L; Chou, T C et al. (1996) Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity. J Med Chem 39:2812-8
Su, T L; Chou, T C; Kim, J Y et al. (1995) 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. J Med Chem 38:3226-35
Sacks, P G; Harris, D; Chou, T C (1995) Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer 61:409-15
Schlemmer, S R; Yang, C H; Sirotnak, F M (1995) Functional modulation of multidrug resistance-related P-glycoprotein by Ca(2+)-calmodulin. J Biol Chem 270:11040-2

Showing the most recent 10 out of 106 publications